KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Tax Provisions (2019 - 2025)

Alnylam Pharmaceuticals' Tax Provisions history spans 10 years, with the latest figure at -$25.3 million for Q4 2025.

  • For Q4 2025, Tax Provisions rose 77.06% year-over-year to -$25.3 million; the TTM value through Dec 2025 reached $9.4 million, up 109.48%, while the annual FY2025 figure was $9.4 million, 109.48% up from the prior year.
  • Tax Provisions reached -$25.3 million in Q4 2025 per ALNY's latest filing, down from -$12.1 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $30.9 million in Q2 2025 to a low of -$110.2 million in Q4 2024.
  • Average Tax Provisions over 5 years is -$3.9 million, with a median of $1.1 million recorded in 2021.
  • Peak YoY movement for Tax Provisions: skyrocketed 13091.3% in 2023, then tumbled 60315.85% in 2024.
  • A 5-year view of Tax Provisions shows it stood at -$1.8 million in 2021, then surged by 125.62% to $472000.0 in 2022, then crashed by 61.23% to $183000.0 in 2023, then crashed by 60315.85% to -$110.2 million in 2024, then soared by 77.06% to -$25.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Tax Provisions are -$25.3 million (Q4 2025), -$12.1 million (Q3 2025), and $30.9 million (Q2 2025).